Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter (BAX) to $22 from $23 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter introduces IV Verify Line Labeling System
- Baxter Names Interim CFO as Board Refresh Continues
- Balanced Risk Profile and Execution Uncertainty Justify Hold Rating on Baxter Post S&P Outlook Downgrade
- Baxter International Appoints Interim CFO Amid Leadership Transition
- Baxter CFO Joel Grade to depart